D002066Chemicals & DrugsD02.033.455.125.125D02.455.326.146.100.050.500.100D02.886.645.600.055.050.510.100140.998493Busulfancmhprofilesont:personsuffixperson suffixprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation Resourcevivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonMD, MPHAlanGamisAlan S. Gamis0.000000000000000.0000000000000049Gamis, Alan0000-0003-1513-2893Chief, Section of Oncology23444282McCune JS, Baker KS, Blough DK, Gamis A, Bemer MJ, Kelton-Rehkopf MC, Winter L, Barrett JSJournal of clinical pharmacologyMcCune JS, Baker KS, Blough DK, Gamis A, Bemer MJ, Kelton-Rehkopf MC, Winter L, Barrett JS. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. J Clin Pharmacol. 2013 Mar; 53(3):264-75.J Clin Pharmacol2013-01-24T00:00:002013Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.24218510McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NHClinical cancer research : an official journal of the American Association for Cancer ResearchMcCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res. 2014 Feb 01; 20(3):754-63.Clin Cancer Res2013-11-11T00:00:002013Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.26660176Deng S, Kiscoan M, Frazee C, Abdel-Rahman S, Dalal J, Garg UMethods in molecular biology (Clifton, N.J.)Deng S, Kiscoan M, Frazee C, Abdel-Rahman S, Dalal J, Garg U. A Simple Liquid Chromatography Tandem Mass Spectrometry Method for Quantitation of Plasma Busulfan. Methods Mol Biol. 2016; 1383:79-87.Methods Mol Biol2016-01-01T00:00:002016A Simple Liquid Chromatography Tandem Mass Spectrometry Method for Quantitation of Plasma Busulfan.26854326Abdel-Rahman SM, Casey KL, Garg U, Dalal JPediatric transplantationAbdel-Rahman SM, Casey KL, Garg U, Dalal J. Intravenous busulfan dose individualization - impact of modeling approach on dose recommendation. Pediatr Transplant. 2016 May; 20(3):443-8.Pediatr Transplant2016-02-08T00:00:002016Intravenous busulfan dose individualization - impact of modeling approach on dose recommendation.PediatricsClinicalChildren's Mercy Kansas City34596937Elgarten CW, Wood AC, Li Y, Alonzo TA, Brodersen LE, Gerbing RB, Getz KD, Huang YV, Loken M, Meshinchi S, Pollard JA, Sung L, Woods WG, Kolb EA, Gamis AS, Aplenc RPediatric blood & cancerElgarten CW, Wood AC, Li Y, Alonzo TA, Brodersen LE, Gerbing RB, Getz KD, Huang YV, Loken M, Meshinchi S, Pollard JA, Sung L, Woods WG, Kolb EA, Gamis AS, Aplenc R. Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 12; 68(12):e29281.Pediatr Blood Cancer2021-10-01T00:00:002021Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group.0.3016010.3016011research area of0.5693570.04910526subject area fortrue1Chief, Section of OncologyChief, Section of Oncology